AI assistant
Sending…
Pluri Inc. — Report Publication Announcement 2021
Nov 8, 2021
6990_rns_2021-11-09_036f3826-f096-4e0f-891f-585a3c60c3c8.htm
Report Publication Announcement
Open in viewerOpens in your device viewer
_________ false
| �������� ��������� ���� | 2 379 |
| PLURISTEM THERAPEUTICS INC | |
| Corporation no: C12337-2001 | 12448 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C001 ( Public ) | Reported via MAGNA: | 09/11/2021 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2021-02-164397 | Time of broadcast: 00:03 00:03 |
Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report on����� Q1
f10q0921_pluristemtherapEDGAR3_Bannerless_isa.pdf
Link to filing on foreign stock exchange (optional): _________
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 19/10/2021 |
| Address: Matam Park 5 , Haifa 31905 ISRAEL , Tel: 074-7107171 , Fax: 074-7107172 | |
| E-mail address: [email protected] Company site: www.pluristem.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Franco Yehuda Chen Position of Signatory in the reporting corporation: CFO & Corporate Secretary Name of Employer Company: | |
| Address: Park matam 20 , Haifa 31905 Telephone: 074-7107171 Facsimile: 074-7107172 E-mail: [email protected] 2 | |
More from Pluri Inc.
Report Publication Announcement
2026
May 14
Interim / Quarterly Report
2026
May 14
Interim / Quarterly Report
2026
May 14
Annual Report
2026
Apr 23
Report Publication Announcement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Capital/Financing Update
2026
Mar 27